JP2023509390A5 - - Google Patents
Info
- Publication number
- JP2023509390A5 JP2023509390A5 JP2022538362A JP2022538362A JP2023509390A5 JP 2023509390 A5 JP2023509390 A5 JP 2023509390A5 JP 2022538362 A JP2022538362 A JP 2022538362A JP 2022538362 A JP2022538362 A JP 2022538362A JP 2023509390 A5 JP2023509390 A5 JP 2023509390A5
- Authority
- JP
- Japan
- Prior art keywords
- apol1
- antibody
- seq
- acid sequence
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025184236A JP2026031975A (ja) | 2019-12-23 | 2025-10-31 | アポリポタンパク質ｌ１特異的抗体及びその使用方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962953097P | 2019-12-23 | 2019-12-23 | |
| US62/953,097 | 2019-12-23 | ||
| PCT/US2020/066377 WO2021133723A2 (en) | 2019-12-23 | 2020-12-21 | Apolipoprotein l1-specific antibodies and methods of use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025184236A Division JP2026031975A (ja) | 2019-12-23 | 2025-10-31 | アポリポタンパク質ｌ１特異的抗体及びその使用方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023509390A JP2023509390A (ja) | 2023-03-08 |
| JP2023509390A5 true JP2023509390A5 (https=) | 2024-01-04 |
Family
ID=74191928
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022538362A Pending JP2023509390A (ja) | 2019-12-23 | 2020-12-21 | アポリポタンパク質ｌ１特異的抗体及びその使用方法 |
| JP2025184236A Pending JP2026031975A (ja) | 2019-12-23 | 2025-10-31 | アポリポタンパク質ｌ１特異的抗体及びその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025184236A Pending JP2026031975A (ja) | 2019-12-23 | 2025-10-31 | アポリポタンパク質ｌ１特異的抗体及びその使用方法 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20230071609A1 (https=) |
| EP (1) | EP4081294A2 (https=) |
| JP (2) | JP2023509390A (https=) |
| KR (1) | KR20220118527A (https=) |
| CN (1) | CN115515678A (https=) |
| AU (1) | AU2020412609A1 (https=) |
| BR (1) | BR112022012439A2 (https=) |
| CA (1) | CA3165504A1 (https=) |
| CL (1) | CL2022001714A1 (https=) |
| CO (1) | CO2022010235A2 (https=) |
| CR (1) | CR20220334A (https=) |
| IL (1) | IL294131A (https=) |
| MX (1) | MX2022007746A (https=) |
| PE (1) | PE20221186A1 (https=) |
| PH (1) | PH12022551496A1 (https=) |
| WO (1) | WO2021133723A2 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL308258A (en) | 2021-05-05 | 2024-01-01 | Immatics Biotechnologies Gmbh | Bma031 antigen binding polypeptides |
| US20250298019A1 (en) * | 2021-11-12 | 2025-09-25 | Virginia Tech Intellectual Properties, Inc. | Borrelia burgdorferi peptidoglycan detection methods |
| MX2024008868A (es) | 2022-01-18 | 2024-09-23 | Maze Therapeutics Inc | Inhibidores de la apolipoproteína l1 (apol1) y métodos de uso. |
| KR20240154675A (ko) * | 2022-03-16 | 2024-10-25 | 주식회사 에스티큐브앤컴퍼니 | Btn1a1 결합 단백질 및 이의 이용 방법 |
| JP2025529210A (ja) * | 2022-09-01 | 2025-09-04 | ユニバーシティ・オブ・ジョージア・リサーチ・ファウンデイション・インコーポレイテッド | アポリポタンパク質ｌ１を導いて哺乳動物の細胞死を誘導するための組成物及び方法 |
| JPWO2024203942A1 (https=) * | 2023-03-24 | 2024-10-03 | ||
| WO2024233792A2 (en) * | 2023-05-09 | 2024-11-14 | Virginia Tech Intellectual Properties, Inc. | B. burgdorferi peptidoglycan antibodies and uses thereof |
| KR20260029504A (ko) * | 2023-05-22 | 2026-03-04 | 앨버트 아인슈타인 컬리지 오브 메디신 | S100 단백질을 표적으로 하는 항체 및 이의 용도 |
| AU2024346686A1 (en) * | 2023-09-23 | 2026-04-16 | Agilent Technologies, Inc. | Anti-human adam9 antibodies for in vitro diagnostics |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| EP0368684B2 (en) | 1988-11-11 | 2004-09-29 | Medical Research Council | Cloning immunoglobulin variable domain sequences. |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
| US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
| US7018809B1 (en) | 1991-09-19 | 2006-03-28 | Genentech, Inc. | Expression of functional antibody fragments |
| FI941572A7 (fi) | 1991-10-07 | 1994-05-27 | Oncologix Inc | Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä |
| CA2372813A1 (en) | 1992-02-06 | 1993-08-19 | L.L. Houston | Biosynthetic binding protein for cancer marker |
| DK0752248T3 (da) | 1992-11-13 | 2000-11-13 | Idec Pharma Corp | Terapeutisk anvendelse af kimæriske og radioaktivt mærkede antistoffer mod humant B-lymfocytbegrænset differentieringsantig |
| US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| ATE299938T1 (de) | 1997-05-02 | 2005-08-15 | Genentech Inc | Ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen |
| US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
| DK1034298T3 (da) | 1997-12-05 | 2012-01-30 | Scripps Research Inst | Humanisering af murint antistof |
| JP2003505082A (ja) | 1999-07-26 | 2003-02-12 | ジェネンテック・インコーポレーテッド | 新規なポリヌクレオチドとその使用法 |
| ES2248127T3 (es) | 1999-10-04 | 2006-03-16 | Medicago Inc. | Metodo para regular la transcripcion de genes foraneos en presencia de nigtrogeno. |
| US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
| JP2003531588A (ja) | 2000-04-11 | 2003-10-28 | ジェネンテック・インコーポレーテッド | 多価抗体とその用途 |
| JP2008501621A (ja) | 2003-05-31 | 2008-01-24 | マイクロメット アクツィエン ゲゼルシャフト | Ｂ細胞関連疾患を処置するための二重特異性抗ｃｄ３、抗ｃｄ１９抗体構築物を含む薬学的組成物 |
| US7235641B2 (en) | 2003-12-22 | 2007-06-26 | Micromet Ag | Bispecific antibodies |
| EP1740615B1 (en) | 2004-03-31 | 2014-11-05 | Genentech, Inc. | Humanized anti-tgf-beta antibodies |
| EP1940881B1 (en) | 2005-10-11 | 2016-11-30 | Amgen Research (Munich) GmbH | Compositions comprising cross-species-specific antibodies and uses thereof |
| US20080044455A1 (en) | 2006-08-21 | 2008-02-21 | Chaim Welczer | Tonsillitus Treatment |
| WO2008027236A2 (en) | 2006-08-30 | 2008-03-06 | Genentech, Inc. | Multispecific antibodies |
| DE102007001370A1 (de) | 2007-01-09 | 2008-07-10 | Curevac Gmbh | RNA-kodierte Antikörper |
| RS53008B2 (sr) | 2007-04-03 | 2022-12-30 | Amgen Res Munich Gmbh | Interspecijski specifičan cd3-epsilon vezujući domen |
| US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
| US8242247B2 (en) | 2007-12-21 | 2012-08-14 | Hoffmann-La Roche Inc. | Bivalent, bispecific antibodies |
| US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
| JP6157046B2 (ja) | 2008-01-07 | 2017-07-05 | アムジェン インコーポレイテッド | 静電的ステアリング（ｅｌｅｃｔｒｏｓｔａｔｉｃｓｔｅｅｒｉｎｇ）効果を用いた抗体Ｆｃヘテロ二量体分子を作製するための方法 |
| CA2756244A1 (en) | 2009-04-02 | 2010-10-07 | Roche Glycart Ag | Multispecific antibodies comprising full length antibodies and single chain fab fragments |
| SG175077A1 (en) | 2009-04-07 | 2011-11-28 | Roche Glycart Ag | Trivalent, bispecific antibodies |
| PE20120540A1 (es) | 2009-05-27 | 2012-05-09 | Hoffmann La Roche | Anticuerpos triespecificos o tetraespecificos |
| US9676845B2 (en) | 2009-06-16 | 2017-06-13 | Hoffmann-La Roche, Inc. | Bispecific antigen binding proteins |
| EP2478013B1 (en) | 2009-09-16 | 2018-10-24 | F.Hoffmann-La Roche Ag | Coiled coil and/or tether containing protein complexes and uses thereof |
| WO2013026839A1 (en) | 2011-08-23 | 2013-02-28 | Roche Glycart Ag | Bispecific antibodies specific for t-cell activating antigens and a tumor antigen and methods of use |
| NO2748201T3 (https=) | 2011-08-23 | 2018-05-12 | ||
| EP2748202B1 (en) | 2011-08-23 | 2018-07-04 | Roche Glycart AG | Bispecific antigen binding molecules |
| CN105849124B (zh) | 2013-12-20 | 2022-04-12 | 豪夫迈·罗氏有限公司 | 双重特异性抗体 |
| UA117289C2 (uk) | 2014-04-02 | 2018-07-10 | Ф. Хоффманн-Ля Рош Аг | Мультиспецифічне антитіло |
| EP3174897B1 (en) | 2014-07-29 | 2020-02-12 | F.Hoffmann-La Roche Ag | Multispecific antibodies |
| EP3177643B1 (en) | 2014-08-04 | 2019-05-08 | F.Hoffmann-La Roche Ag | Bispecific t cell activating antigen binding molecules |
| CN107105632A (zh) * | 2014-11-10 | 2017-08-29 | 豪夫迈·罗氏有限公司 | 肾病动物模型及其治疗剂 |
| WO2016172485A2 (en) | 2015-04-24 | 2016-10-27 | Genentech, Inc. | Multispecific antigen-binding proteins |
-
2020
- 2020-12-21 KR KR1020227025218A patent/KR20220118527A/ko active Pending
- 2020-12-21 WO PCT/US2020/066377 patent/WO2021133723A2/en not_active Ceased
- 2020-12-21 AU AU2020412609A patent/AU2020412609A1/en not_active Abandoned
- 2020-12-21 EP EP20842842.5A patent/EP4081294A2/en active Pending
- 2020-12-21 JP JP2022538362A patent/JP2023509390A/ja active Pending
- 2020-12-21 CR CR20220334A patent/CR20220334A/es unknown
- 2020-12-21 PE PE2022001163A patent/PE20221186A1/es unknown
- 2020-12-21 CA CA3165504A patent/CA3165504A1/en active Pending
- 2020-12-21 MX MX2022007746A patent/MX2022007746A/es unknown
- 2020-12-21 CN CN202080096952.1A patent/CN115515678A/zh active Pending
- 2020-12-21 PH PH1/2022/551496A patent/PH12022551496A1/en unknown
- 2020-12-21 BR BR112022012439A patent/BR112022012439A2/pt not_active Application Discontinuation
- 2020-12-21 IL IL294131A patent/IL294131A/en unknown
-
2022
- 2022-06-22 CL CL2022001714A patent/CL2022001714A1/es unknown
- 2022-06-22 US US17/846,744 patent/US20230071609A1/en active Pending
- 2022-07-19 CO CONC2022/0010235A patent/CO2022010235A2/es unknown
-
2025
- 2025-10-31 JP JP2025184236A patent/JP2026031975A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023509390A5 (https=) | ||
| JP7019198B2 (ja) | 補体関連疾患の予防及び治療のためのｃ５抗体及び方法 | |
| CN109937212B (zh) | B7-h3抗体、其抗原结合片段及其医药用途 | |
| TWI673287B (zh) | 抗b7-h3抗體、其抗原結合片段及其醫藥用途 | |
| JP2019527553A5 (https=) | ||
| JP2011527899A5 (https=) | ||
| JP2018516853A5 (https=) | ||
| WO2018023976A1 (zh) | 抗人ifnar1的抗体及其用途 | |
| CA2583910A1 (en) | Angiopoietin-2 specific binding agents | |
| JP2023551027A5 (https=) | ||
| KR20070084069A (ko) | Ｔｎｆｒ1에 대한 단일 도메인 항체 및 이의 사용 방법 | |
| JP2021530244A5 (https=) | ||
| JP2023520969A5 (https=) | ||
| JP2017521054A5 (https=) | ||
| CN106243223B (zh) | 抗人pdl1抗体及其用途 | |
| JP2024001073A5 (https=) | ||
| JP2023510787A (ja) | 抗ａｎｇｐｔｌ３抗体及びその応用 | |
| JP2025505650A5 (https=) | ||
| JP7717687B2 (ja) | 腎疾患における抗幹細胞因子抗体及びその使用方法 | |
| JP2024541668A5 (https=) | ||
| JP2024516098A5 (https=) | ||
| WO2026012501A1 (zh) | 一种抗ngf单克隆抗体及其应用 | |
| CN103588882A (zh) | 针对人cd22抗体的抗独特型抗体及其应用 | |
| US20230242677A1 (en) | Multi-specific antibodies | |
| CN113651884A (zh) | 人源化抗SARS-CoV-2单克隆抗体及其应用 |